Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Subscribe to Selected New Research on Chronic Inflammatory Demyelinating Polyradiculoneuropathy

407 relevant articles (75 outcomes, 84 trials/studies) found for this Disease

Description: A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)

Also Known As:

CIDP; Polyradiculoneuropathy, Chronic Inflammatory; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Chronic Inflammatory Polyradiculoneuropathy; Inflammatory Polyradiculopathy, Chronic; Chronic Inflammatory Polyradiculoneuropathies; Chronic Inflammatory Polyradiculopathies; Chronic Inflammatory Polyradiculopathy; Inflammatory Polyradiculopathies, Chronic; Polyradiculoneuropathies, Chronic Inflammatory; Polyradiculopathies, Chronic Inflammatory; Polyradiculopathy, Chronic Inflammatory

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3406

Demyelinating Diseases: 3164

Polyradiculoneuropathy: 170

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 407

Neuromuscular Diseases: 742

Peripheral Nervous System Diseases: 3224

Polyneuropathies: 2632

Polyradiculoneuropathy: 170

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 407

Autoimmune Diseases of the Nervous System: 16

Polyradiculoneuropathy: 170

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 407

Immune System Diseases: 1232

Autoimmune Diseases: 11535

Autoimmune Diseases of the Nervous System: 16

Polyradiculoneuropathy: 170

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 407

Related Diseases

1.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
2.	Polyneuropathies (Polyneuropathy)
3.	Syndrome
4.	Myasthenia Gravis
5.	Inclusion Body Myositis

Experts

1.	Hughes, R A C: 4 articles (04/2006 - 05/2002)
2.	Mehndiratta, M M: 3 articles (01/2004 - 01/2001)
3.	Hughes, R A: 3 articles (01/2003 - 01/2001)
4.	Nobile-Orazio, Eduardo: 2 articles (07/2008 - 11/2003)
5.	Dalakas, Marinos C: 2 articles (02/2008 - 11/2003)
6.	Hughes, Richard A C: 2 articles (02/2008 - 06/2005)
7.	Vermeulen, Marinus: 2 articles (02/2008 - 12/2002)
8.	Brannagan, Thomas H: 2 articles (10/2007 - 12/2002)
9.	Morita, Hiroshi: 2 articles (07/2006 - 09/2004)
10.	Ikeda, Shu-ichi: 2 articles (07/2006 - 09/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

1.	Intravenous Immunoglobulins (IVIG)FDA Link 07/01/2008 - "The results of this ICE trial demonstrated the efficacy of IVIg in CIDP, with a significantly higher response rate versus placebo after 24 weeks of treatment (P = 0.0002)" 08/01/1996 - "Of the 30 patients, 19 (63%) improved with IvIg treatments; nine out of 16 patients (56%) with chronic progressive CIDP, and 10 out of 14 patients (71%) with relapsing CIDP (differences were not statistically significant)" 06/01/1991 - "High-dose IVIG was a safe and effective adjunctive therapy for childhood CIDP in these four patients." 07/01/2008 - "On the basis of available data, IVIg can be recommended as a first-line treatment option for GBS and CIDP" 12/09/2003 - "In a pilot study on 10 CIDP-DM patients with IV immunoglobulins and tight glycemic control, the CIDP-DM patients had a better outcome than DNP patients treated with tight glycemic control only." Order ALL the reference details at left...
2.	Immunoglobulins (Immunoglobulin)IBA 03/01/2006 - "Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy]" 01/01/2002 - "OBJECTIVES: To review systematically the evidence from randomised controlled trials concerning the efficacy and safety of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy" 03/01/1996 - "A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy." 08/01/2008 - "Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a multiracial Asian perspective." 06/01/2008 - "CONCLUSIONS: When patients with MS develop CIDP, manifestations of central and peripheral disease involvement seem to respond to intravenous immunoglobulin" Order ALL the reference details at left...
3.	Adrenal Cortex Hormones (Corticosteroids)IBA 03/26/2002 - "Patients with apparent GBS who show persistent symptoms may benefit from corticosteroids or other treatment that is beneficial in the management of CIDP." 01/01/2002 - "OBJECTIVES: To evaluate the efficacy of corticosteroids for treating chronic inflammatory demyelinating polyradiculoneuropathy" 01/01/2001 - "OBJECTIVES: To evaluate the efficacy of corticosteroids for treating chronic inflammatory demyelinating polyradiculoneuropathy" 01/01/2002 - "REVIEWER'S CONCLUSIONS: A single randomised controlled trial with 35 participants provided weak evidence to support the conclusion from non-randomised studies that oral corticosteroids reduce impairment in chronic inflammatory demyelinating polyradiculoneuropathy" 01/01/2001 - "REVIEWER'S CONCLUSIONS: A single randomised controlled trial with 35 participants provided weak evidence to support the common opinion derived from non-randomised studies that oral corticosteroids reduce impairment in chronic inflammatory demyelinating polyradiculoneuropathy" Order ALL the reference details at left...
4.	Prednisone (Sone)FDA LinkGeneric 03/01/2000 - "The occurrence of the oedema in a person with CIDP and FSGN and its improvement with prednisone, together with improvement in CIDP and FSGN, suggests that it was immune mediated, possibly due to increased capillary permeability" 01/01/1978 - "Suggestive preliminary evidence from controlled 3-month clinical trials that prednisone improves chronic inflammatory polyradiculoneuropathy." 09/01/2007 - "The patient had initially a sensory CIDP wich respond to prednisone" 04/01/1982 - "These cases may represent a chance association of chronic inflammatory-demyelinating polyradiculoneuropathy and hereditary motor and sensory neuropathy, a causally linked association of these disorders, or a prednisone-responsive inherited neuropathy only" 02/01/1982 - "This finding provides further justification for classifying progressive with recurrent cases as CIDP and demonstrates that prednisone treatment should not be withheld from patients with progressive disease." Order ALL the reference details at left...
5.	SteroidsIBA 01/01/1994 - "These differences may explain the empirical observations that steroids are helpful in CIDP but not GBS" 10/01/2002 - "Whether steroids not only suppress disease activity in CIDP but also eradicate the disease remains to be established" 05/01/1998 - "This report highlights the different response to therapy of MMN and chronic inflammatory demyelinating polyneuropathy (CIDP) because not only steroids but also PE, which is often effective in CIDP, do not improve and at times may even worsen MMN." 09/01/2003 - "Progressive muscle weakness after high-dose steroids in two children with CIDP." 04/01/2003 - "Although rare, phrenic nerve palsy may be a feature of CIDP and may be responsive to treatment with i.v.Ig or steroids." Order ALL the reference details at left...
6.	AntibodiesIBA 06/01/2005 - "The frequency of such antibodies was significantly greater in both CIDP (p = 0.04) and GBS (p = 0.003) patients than in normal control subjects" 09/01/1995 - "It was concluded that these antibodies may help to distinguish CIDP from other neuropathies and that they are diagnostically useful" 02/01/2006 - "Thirty-eight percent of GBS patients and 28% of CIDP patients had detectable serum titers of anti-ganglioside antibodies, which were associated with a high incidence of motor conduction block and increased F wave latencies" 03/01/2002 - "Detailed immunopathologic features have been described in GBS and CIDP: most current investigations are centered on the hypothesis of molecular mimicry in GBS and together with the pathogenic role of cell-mediated immunity different antibodies have been discovered in GBS which interfere with nerve impulse conduction on neuromuscular transmission" 05/01/2000 - "Antibodies were detected by both methods in 52% of patients with GBS, 35% with CIDP, 3% with ONP and no normal controls" Order ALL the reference details at left...
7.	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/01/2006 - "The author reports the long-term therapeutic efficacy of ciclosporin for patients with CIDP who did not show sustained improvement under steroid therapy" 11/01/2005 - "This study demonstrates the efficacy of cyclosporine included in a regimen for the treatment of steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy in two children" 11/01/2005 - "We conclude that cyclosporine is an effective drug in the treatment of children with steroid-resistant chronic inflammatory demyelinating polyradiculoneuropathy." 11/01/2005 - "Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy." 09/15/2004 - "Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy." Order ALL the reference details at left...
8.	InterferonsIBA 01/01/2004 - "OBJECTIVES: We aimed to review systematically the evidence from randomised trials concerning cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy" 01/01/2003 - "OBJECTIVES: We aimed to review systematically the evidence from randomised trials concerning cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy" 01/01/2004 - "Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy." 01/01/2003 - "Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy." 03/01/2002 - "New insight in the pathogenetic role of the cytokine-network in CIDP opens new therapeutical possibilities with the modification of the T-1 helper cell reaction with interferon." Order ALL the reference details at left...
9.	rituximab (Mabthera)FDA Link 08/24/2004 - "Rituximab may represent a successful therapy in otherwise refractory CIDP." 07/01/2006 - "Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine." 11/01/2004 - "Rituximab-responsive CIDP." 08/24/2004 - "A therapeutic approach with the chimeric monoclonal anti-CD20 antibody rituximab induced substantial improvement of CIDP and hematologic recovery" 08/01/2008 - "Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura." Order ALL the reference details at left...
10.	Interferon-betaIBA 04/01/2003 - "Preliminary studies have evaluated the effects of interferon beta formulations in the treatment of CIDP, one of which has shown promising results and warrants further investigation." 02/01/1998 - "Interferon beta might represent an adjunctive therapy in CIDP both acting on a defective blood-nerve barrier and normalizing an otherwise defective suppressor cell function." 03/01/1995 - "Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy." 04/01/2003 - "One class of immunomodulators, interferon beta formulations, has proven efficacy in the treatment of MS, and because of clinical similarities between the two diseases it is attractive to investigate whether some agents that are effective in the treatment of MS would also be effective in CIDP" 01/01/2004 - "REVIEWERS' CONCLUSIONS: The evidence is inadequate to decide whether azathioprine, interferon beta or any other immunosuppressive drug or interferon is beneficial in chronic inflammatory demyelinating polyradiculoneuropathy." Order ALL the reference details at left...

Therapies and Procedures

1.	Plasma Exchange 05/01/1985 - "Results in this unselected, consecutive patient trial suggest a temporal relationship between plasma exchange and clinical improvement in some patients with progressive CIDP." 01/01/1982 - "It is too early to draw any conclusion from these studies other than that the double-blind study employed here is feasible and should provide information on the efficacy of plasma exchange in CIDP if its effect is prompt and large" 01/01/2004 - "OBJECTIVES: To evaluate the efficacy of plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy" 07/01/1989 - "Chronic inflammatory demyelinating polyradiculoneuropathy of acute onset: relapse after temporary improvement by plasma exchange and longstanding remission by corticosteroid therapy]" 08/01/1988 - "Four patients with clinical, electrophysiologic, and histologic evidence of CIDP and severe progressive weakness improved with plasma exchange, three regaining normal function." Order ALL the reference details at left...
2.	Plasmapheresis 03/01/1998 - "We were not able to determine whether immunoadsorption plasmapheresis or double-filtration plasmapheresis was more effective for the patients with CIDP" 03/01/1998 - "The present study strongly suggests that plasmapheresis with concomitant steroid therapy is very useful for both short- and long-term treatment of CIDP patients." 08/01/1998 - "We conclude that DFPP was useful for the subgroups of CIDP patients, but the underlying immuno-pathological background that determine the efficacy of plasmapheresis should be elucidated." 07/01/2007 - "This review evaluates the role of plasmapheresis in CIDP." 07/01/2007 - "Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy." Order ALL the reference details at left...
3.	Aftercare (After-Treatment) 09/01/2005 - "We here initially retrospectively analyzed the motor nerve conduction study results of 20 consecutive patients with a clinical diagnosis of CIDP (four performed prior to, and 16 after, treatment initiation) to assess the sensitivity of six published sets of criteria (Nicolas et al., 2002; Thaisetthawatkul et al., 2002; Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce, 1991; Magda et al., 2003; Hughes et al., 2001; Saperstein et al., 2001), as well as four combinations (Nicolas et al., 2002; Ad Hoc Subcommittee of the American Academy of Neurology AIDS Taskforce, 1991; Hughes et al., 2001; Saperstein et al., 2001, each individually combined with Thaisetthawatkul et al., 2002)" 07/01/2008 - "OBJECTIVE: To report a case of a patient with tremor associated with chronic inflammatory demyelinating neuropathy (CIDP) that improved after treatment with pregabalin" 08/30/2008 - "Low levels of TNFR1 were detected on monocytes in the subgroup of patients with CIDP examined after treatment with intravenous immunoglobulin" Order ALL the reference details at left...
4.	Hematopoietic Stem Cell Transplantation 08/01/2007 - "CIDP cured by allogeneic hematopoietic stem cell transplantation." 09/01/2007 - "Chronic inflammatory demyelinating polyradiculoneuropathy in chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: case report." 09/01/2007 - "The chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an unusual but important complication of hematopoietic stem cell transplantation (HSCT) rarely reported to date" Order ALL the reference details at left...
5.	Transplants (Transplant) 05/01/2005 - "Since then, the therapeutic efficacy of IVIg has been established in Guillain Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Chronic Inflammatory Demyelinating Polyradiculoneuropathy

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 75 Outcomes
Top 184 Key Drugs and Biologics
Top 19 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>